Thermo Fisher Hopes to Build LC Portfolio — And Enrich MS Play — Through Bolt-On Buys | GenomeWeb
A dominant presence in the mass spectrometry space, Thermo Fisher Scientific has been almost an afterthought when it comes to liquid chromatography despite the launch of its Accela high-speed liquid chromatographer almost a year ago.
Now, the company hopes to grow its LC play, and will rely on bolt-on acquisitions to do so, according to CEO Marijn Dekkers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.